应用 |
An alkylphospholipid which inhibits Akt activation and the anti-apoptotic MAPK pathway. |
产品介绍 |
Perifosine (KRX-0401)是一种新型的Akt抑制剂,IC50为4.7 μM,靶向作用于Akt的pleckstrin homology (PH)区。Phase 3。 |
备注 |
Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM, targets pleckstrin homology domain of Akt. Phase 2. |
生化机理 |
Perifosine (also KRX-0401) is an alkylphospholipid (octadecyl-(1,1-dimethyl-4-piperidylio) phosphate) which inhibits Akt activation. Perifosine has been studied for potential treatment of a wide variety of cancers. Targeting cellular membranes, Perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. Perifosine also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. Perifosine has a lower gastrointestinal toxicity profile than the related agent Miltefosine. |
别名 |
哌立福新;(1,1-二甲基哌啶-1-鎓-4-基)十八烷基磷酸酯;KRX-0401; NSC 639966;D-21266;KRX 0401;KRX0401;D21266;D 21266;(1,1-Dimethylpiperidin-1-ium-4-yl) octadecyl phosphate; 4-((Hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethylpiperidinium inner salt |